Edition:
United States

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.42EUR
6:19am EST
Change (% chg)

€0.07 (+2.98%)
Prev Close
€2.35
Open
€2.35
Day's High
€2.46
Day's Low
€2.34
Volume
71,422
Avg. Vol
121,695
52-wk High
€3.53
52-wk Low
€2.15

Latest Key Developments (Source: Significant Developments)

PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan
Monday, 18 Dec 2017 12:45am EST 

Dec 18 (Reuters) - PAION AG ::SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN.EUR 1 MILLION UPFRONT PAYMENT TO PAION.ADDITIONAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO EUR 25 MILLION.ROYALTIES RANGING FROM LOW DOUBLE-DIGITS TO OVER 20%.  Full Article

PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
Tuesday, 14 Nov 2017 04:15am EST 

Nov 14 (Reuters) - PAION AG :‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT.‍NO SECOND INTRANASAL STUDY REQUIRED​.‍ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN U.S. AS COMPLETED​.  Full Article

PAION ‍9-mth net loss at 8.5 mln euros
Wednesday, 8 Nov 2017 01:30am EST 

Nov 8 (Reuters) - PAION AG :DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017.‍CASH POSITION OF EUR 29.6 MILLION AS OF 30 SEPTEMBER 2017​.‍REVENUES IN FIRST NINE MONTHS OF 2017 AMOUNTED TO KEUR 5,097 COMPARED TO KEUR 2,230 IN PRIOR-YEAR PERIOD​.‍RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO KEUR 13,528 IN FIRST NINE MONTHS OF 2017​.‍9MTH NET LOSS AMOUNTED TO KEUR 8,508. IN PRIOR-YEAR PERIOD, A NET LOSS OF KEUR 16,061 WAS REPORTED​.‍CONFIRMS ITS OUTLOOK FOR FY ANNOUNCED ON 09 AUGUST 2017 WITH PUBLICATION OF HALF-YEAR RESULTS FOR 2017​.  Full Article

Paion: Japan patent office grants dosing patent for remimazolam
Friday, 13 Oct 2017 04:00am EDT 

Oct 13 (Reuters) - PAION AG ::DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN.‍PATENT PROTECTION UNTIL 2033 IN JAPANESE MARKET​.  Full Article

Paion H1 net loss narrows to 5.8 million euros
Wednesday, 9 Aug 2017 01:30am EDT 

Aug 9 (Reuters) - PAION AG ::‍IN FIRST HALF-YEAR 2017, REVENUES WERE EUR 4.1 MILLION​.‍NET LOSS FOR FIRST HALF-YEAR 2017 WAS EUR 5.8 MILLION COMPARED TO A NET LOSS OF EUR 13.2 MILLION IN PRIOR-YEAR PERIOD​.‍H1 RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO EUR 9.9 MILLION, A DECREASE OF EUR 2.2 MILLION COMPARED TO FIRST HALF-YEAR 2016​.‍IN 2017, PAION EXPECTS REVENUES OF APPROXIMATELY EUR 5.8 MILLION​.FY ‍NET LOSS IS EXPECTED TO BE BETWEEN EUR 12 MILLION AND EUR 14 MILLION, A DECREASE COMPARED TO PRIOR YEAR (2016: EUR 20.1 MILLION)​.  Full Article

Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial
Wednesday, 28 Jun 2017 02:15pm EDT 

June 28 (Reuters) - Paion Ag ::Positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing bronchoscopy.Primary efficacy endpoint successfully achieved.Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial in procedural sedation in patients undergoing bronchoscopy.  Full Article

Paion Q1 revenues at EUR 2.051 mln
Wednesday, 10 May 2017 01:44am EDT 

May 10 (Reuters) - PAION AG ::PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2017.REVENUES IN Q1 OF 2017 AMOUNTED TO EUR 2.051 MLN COMPARED TO EUR 3 MLN IN PRIOR-YEAR PERIOD.NET LOSS FOR Q1 2017 AMOUNTED TO EUR 2.218 MLN.CASH AND CASH EQUIVALENTS DECREASED BY EUR 1.379 MLN IN Q1 2017.PAION CONFIRMS ITS OUTLOOK FOR 2017 MADE ON 16 MARCH 2017 WITH PUBLICATION OF 2016 FINANCIAL RESULTS.PAION'S MAJOR GOALS FOR 2017 ARE CONTINUATION AND COMPLETION OF ONGOING CLINICAL DEVELOPMENT PROGRAM IN U.S. AND HANDOVER OF COMPLETED WORK TO COSMO.POSITIVE DATA ANNOUNCED IN U.S. SAFETY TRIAL WITH REMIMAZOLAM IN HIGH-RISK COLONOSCOPY PATIENTS.FINANCIAL RESULTS IN LINE WITH PLAN.  Full Article

Paion FY net loss shrinks to 20.1 million euros
Thursday, 16 Mar 2017 02:30am EDT 

Paion AG : Cash position of 30.1 million euros ($32.32 million) as of Dec. 31, 2016 . FY revenues amounted to 4.3 million euros in reporting period, an increase of 4.2 million euros compared to previous year . FY research and development costs amounted to 23.4 million euros, a decrease of 6.0 million euros compared to prior year . Net loss of 20.1 million euros was below range of 24.5 million euros to 27.5 million euros projected for fiscal year 2016 (2015: 28.2 million euros) . Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy . To conduct a phase III program in EU, paion currently expects funding needs of approximately 20 million to 25 million euros up until filing, subject to further discussions with regulatory authorities . In 2017, Paion expects revenues of approximately 5.8 million euros .Expects research and development expenses to be between approximately 18 million and 20 million euros for 2017, depending on progress of development.  Full Article

Paion AG says COO Jürgen Raths agrees to resign before contract ends
Thursday, 9 Mar 2017 07:20am EST 

Paion AG : Says it made changes in the management board .Says COO Jürgen Raths agreed to resign from office prior to end of his current appointment expiring on August 31, 2017 and will leave management board of company in March 2017.  Full Article

Paion FY revenues up at 4.3 million euros
Tuesday, 7 Feb 2017 02:52am EST 

Paion AG : Capital increase; preliminary, unaudited key group financial figures for 2016 . Net loss in 2016 amounted to 20.1 million euros (previous year: net loss of 28.2 million euros) . Revenues in 2016 amounted to 4.3 million euros (previous year: 0.1 million euros) . Cash and cash equivalents amounted to 30.1 million euros as of 31 december 2016 (31 december 2015: 32.7 million euros) .Should development, filing and approval through cosmo in procedural sedation in U.S. go according to plan, paion will not need additional funding to bring remimazolam to U.S. Market.  Full Article

BRIEF-PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan

* SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN